[HTML][HTML] p53 signaling in cancer progression and therapy

HE Marei, A Althani, N Afifi, A Hasan, T Caceci… - Cancer cell …, 2021 - Springer
The p53 protein is a transcription factor known as the" guardian of the genome" because of
its critical function in preserving genomic integrity. The TP53 gene is mutated in …

[HTML][HTML] CD39/CD73/A2AR pathway and cancer immunotherapy

C Xia, S Yin, KKW To, L Fu - Molecular cancer, 2023 - Springer
Cancer development is closely associated with immunosuppressive tumor
microenvironment (TME) that attenuates antitumor immune responses and promotes tumor …

Harnessing nanomaterials for cancer sonodynamic immunotherapy

S Liang, J Yao, D Liu, L Rao, X Chen… - Advanced …, 2023 - Wiley Online Library
Immunotherapy has made remarkable strides in cancer therapy over the past decade.
However, such emerging therapy still suffers from the low response rates and immune …

Tumor abnormality-oriented nanomedicine design

Q Zhou, J Xiang, N Qiu, Y Wang, Y Piao, S Shao… - Chemical …, 2023 - ACS Publications
Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Advances in systemic therapy for non-small cell lung cancer

M Miller, N Hanna - Bmj, 2021 - bmj.com
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

[HTML][HTML] Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape

Q Wu, L You, E Nepovimova, Z Heger, W Wu… - Journal of hematology & …, 2022 - Springer
Hypoxia, a common feature of the tumor microenvironment in various types of cancers,
weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby …

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

AA Barkal, RE Brewer, M Markovic, M Kowarsky… - Nature, 2019 - nature.com
Ovarian cancer and triple-negative breast cancer are among the most lethal diseases
affecting women, with few targeted therapies and high rates of metastasis. Cancer cells are …

[HTML][HTML] Ovarian cancer immunotherapy and personalized medicine

S Morand, M Devanaboyina, H Staats… - International Journal of …, 2021 - mdpi.com
Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Rho GTPase signaling in cancer progression and dissemination

E Crosas-Molist, R Samain… - Physiological …, 2022 - journals.physiology.org
Rho GTPases are a family of small G proteins that regulate a wide array of cellular
processes related to their key roles controlling the cytoskeleton. Cancer is a multistep …

Delivery technologies for cancer immunotherapy

RS Riley, CH June, R Langer, MJ Mitchell - Nature reviews Drug …, 2019 - nature.com
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …